Klegerman M
Front Med. 2017; 11(1):1-19.
PMID: 28116631
DOI: 10.1007/s11684-017-0497-8.
Del Zoppo G
Drugs. 1997; 54 Suppl 3:90-8; discussion 98-9.
PMID: 9360856
DOI: 10.2165/00003495-199700543-00013.
Del Zoppo G, Wagner S, Tagaya M
Drugs. 1997; 54(1):9-38.
PMID: 9211077
DOI: 10.2165/00003495-199754010-00002.
Herrick A, Illingworth K, Blann A, Hay C, Hollis S, Jayson M
Ann Rheum Dis. 1996; 55(2):122-7.
PMID: 8712862
PMC: 1010106.
DOI: 10.1136/ard.55.2.122.
Kuiper J, VANT HOF A, Otter M, Biessen E, Rijken D, Van Berkel T
Biochem J. 1996; 313 ( Pt 3):775-80.
PMID: 8611154
PMC: 1216977.
DOI: 10.1042/bj3130775.
Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon.
Lau C, McLaren M, Mackay I, Belch J
Ann Rheum Dis. 1993; 52(6):443-8.
PMID: 8323396
PMC: 1005069.
DOI: 10.1136/ard.52.6.443.
Human tissue-type plasminogen activator. Production in continuous serum-free cell culture and rapid purification.
Kruithof E, Schleuning W, Bachmann F
Biochem J. 1985; 226(3):631-6.
PMID: 4039134
PMC: 1144759.
DOI: 10.1042/bj2260631.
The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related.
Erickson L, Hekman C, Loskutoff D
Proc Natl Acad Sci U S A. 1985; 82(24):8710-4.
PMID: 3936043
PMC: 391506.
DOI: 10.1073/pnas.82.24.8710.
Adverse reactions to thrombolytic agents. Implications for coronary reperfusion following myocardial infarction.
Nazari J, Davison R, Kaplan K, Fintel D
Med Toxicol Adverse Drug Exp. 1987; 2(4):274-86.
PMID: 3306267
DOI: 10.1007/BF03259869.
Thrombosis and atherosclerosis: regulatory role of interactions among blood components and endothelium.
Scharf R, Harker L
Blut. 1987; 55(3):131-44.
PMID: 3304475
DOI: 10.1007/BF00320567.
Binding of tissue plasminogen activator to cultured human endothelial cells.
Hajjar K, Hamel N, HARPEL P, Nachman R
J Clin Invest. 1987; 80(6):1712-9.
PMID: 3119664
PMC: 442444.
DOI: 10.1172/JCI113262.
Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells.
Knudsen B, HARPEL P, Nachman R
J Clin Invest. 1987; 80(4):1082-9.
PMID: 3116043
PMC: 442350.
DOI: 10.1172/JCI113164.
Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats.
Rijken D, Emeis J
Biochem J. 1986; 238(3):643-6.
PMID: 3099771
PMC: 1147186.
DOI: 10.1042/bj2380643.
Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin.
Verheijen J, Caspers M, Chang G, de Munk G, Pouwels P
EMBO J. 1986; 5(13):3525-30.
PMID: 3030730
PMC: 1167389.
DOI: 10.1002/j.1460-2075.1986.tb04678.x.
Binding of urokinase to specific receptor sites on human breast cancer membranes.
Needham G, Sherbet G, Farndon J, Harris A
Br J Cancer. 1987; 55(1):13-6.
PMID: 3028459
PMC: 2001562.
DOI: 10.1038/bjc.1987.3.
Assignment of the human tissue-type plasminogen activator gene (PLAT) to chromosome 8.
Verheijen J, Visse R, Wijnen J, Chang G, Kluft C, Meera Khan P
Hum Genet. 1986; 72(2):153-6.
PMID: 3002960
DOI: 10.1007/BF00283935.
Antithrombin III activity (residual thrombin activity) in plasma from non-medicated or heparinized horses.
Darien B, Potempa J, Moore J, Travis J
Vet Res Commun. 1989; 13(1):31-46.
PMID: 2773304
DOI: 10.1007/BF00366851.
Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells.
Gelehrter T
J Clin Invest. 1986; 77(1):165-9.
PMID: 2418059
PMC: 423322.
DOI: 10.1172/JCI112271.
Guidelines on the investigation and management of thrombophilia. The British Committee for Standards in Haematology.
J Clin Pathol. 1990; 43(9):703-9.
PMID: 2212062
PMC: 502744.
DOI: 10.1136/jcp.43.9.703.
Binding of tissue plasminogen activator to human aortic endothelial cells.
Sanzo M, Howard S, Wittwer A, Cochrane H
Biochem J. 1990; 269(2):475-82.
PMID: 2117440
PMC: 1131601.
DOI: 10.1042/bj2690475.
